Inovio Pharmaceuticals Stock Last Dividend Paid
INO Stock | USD 4.32 0.13 3.10% |
Inovio Pharmaceuticals fundamentals help investors to digest information that contributes to Inovio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharmaceuticals stock.
Inovio | Last Dividend Paid |
Inovio Pharmaceuticals Company Last Dividend Paid Analysis
Inovio Pharmaceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Inovio Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Inovio Additional Paid In Capital
Additional Paid In Capital |
|
Based on the recorded statements, Inovio Pharmaceuticals has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
All Next | Launch Module |
Inovio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inovio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inovio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Inovio Fundamentals
Return On Equity | -0.91 | ||||
Return On Asset | -0.4 | ||||
Operating Margin | (329.46) % | ||||
Current Valuation | 37 M | ||||
Shares Outstanding | 26.1 M | ||||
Shares Owned By Insiders | 0.84 % | ||||
Shares Owned By Institutions | 33.51 % | ||||
Number Of Shares Shorted | 3.75 M | ||||
Price To Earning | (5.43) X | ||||
Price To Book | 1.49 X | ||||
Price To Sales | 190.51 X | ||||
Revenue | 832.01 K | ||||
Gross Profit | (177.39 M) | ||||
EBITDA | (130.39 M) | ||||
Net Income | (135.12 M) | ||||
Cash And Equivalents | 348.13 M | ||||
Cash Per Share | 1.40 X | ||||
Total Debt | 30.21 M | ||||
Debt To Equity | 0.11 % | ||||
Current Ratio | 3.17 X | ||||
Book Value Per Share | 5.15 X | ||||
Cash Flow From Operations | (124.37 M) | ||||
Short Ratio | 11.22 X | ||||
Earnings Per Share | (4.43) X | ||||
Target Price | 10.67 | ||||
Number Of Employees | 127 | ||||
Beta | 0.83 | ||||
Market Capitalization | 112.75 M | ||||
Total Asset | 172.94 M | ||||
Retained Earnings | (1.62 B) | ||||
Working Capital | 110.54 M | ||||
Current Asset | 171.85 M | ||||
Current Liabilities | 31.47 M | ||||
Net Asset | 172.94 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.